ID   IGR-1
AC   CVCL_1303
SY   IGR 1; IGR1; Institut Gustave Roussy-1
DR   CLO; CLO_0006669
DR   CLDB; cl2624
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 639
DR   BioSample; SAMN03472901
DR   BioSample; SAMN10987998
DR   cancercelllines; CVCL_1303
DR   Cell_Model_Passport; SIDM01060
DR   ChEMBL-Cells; CHEMBL3308749
DR   ChEMBL-Targets; CHEMBL1075479
DR   CLS; 300219
DR   CLS; 300219-SF
DR   Cosmic; 907169
DR   Cosmic; 2230115
DR   Cosmic-CLP; 907169
DR   DepMap; ACH-000882
DR   DSMZ; ACC-236
DR   DSMZCellDive; ACC-236
DR   EGA; EGAS00001000978
DR   GDSC; 907169
DR   GEO; GSM887157
DR   GEO; GSM888229
DR   GEO; GSM1669927
DR   IARC_TP53; 21394
DR   LiGeA; CCLE_169
DR   LINCS_LDP; LCL-1247
DR   PharmacoDB; IGR1_651_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1303
DR   PubChem_Cell_line; CVCL_1303
DR   Wikidata; Q54897358
RX   PubMed=405430;
RX   PubMed=954556;
RX   PubMed=1822769;
RX   PubMed=4153924;
RX   PubMed=6929009;
RX   PubMed=11668190;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=25056119;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~75-100 hours (DSMZ=ACC-236).
CC   HLA typing: A*02:01:01,03:01:01; B*11:01:01,44:02:01; C*04:01:01,05:01:01; DPB1*04:01:01G,04:02:01G; DQA1*01:01:01,03:03:01; DQB1*03:01:01,05:01:01; DRB1*01:01:01,04:01:01 (CLS=300219).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=25056119; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Pro29Ser (c.85C>T); ClinVar=VCV000376362; Zygosity=Heterozygous (PubMed=25056119; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.53%; Native American=0%; East Asian, North=2.53%; East Asian, South=0%; South Asian=0.58%; European, North=60.87%; European, South=35.49% (PubMed=30894373).
CC   Derived from site: Metastatic; Inguinal lymph node; UBERON=UBERON_0001542.
ST   Source(s): CLS; Cosmic-CLP; DSMZ; PubMed=25056119; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 13
ST   D16S539: 11 (PubMed=25056119)
ST   D16S539: 11,13 (CLS; Cosmic-CLP; DSMZ; PubMed=25877200)
ST   D18S51: 14,16 (DSMZ; PubMed=25877200)
ST   D18S51: 16 (CLS)
ST   D19S433: 15,16
ST   D21S11: 32.2
ST   D2S1338: 20,22
ST   D3S1358: 14,17
ST   D5S818: 10,11 (CLS; Cosmic-CLP; DSMZ; PubMed=25877200)
ST   D5S818: 10,14 (PubMed=25056119)
ST   D7S820: 10,11
ST   D8S1179: 10 (CLS)
ST   D8S1179: 10,14 (DSMZ; PubMed=25056119; PubMed=25877200)
ST   FGA: 23,24
ST   Penta D: 10
ST   Penta E: 7,11
ST   TH01: 7,9.3 (CLS)
ST   TH01: 9.3 (Cosmic-CLP; DSMZ; PubMed=25056119; PubMed=25877200)
ST   TPOX: 8
ST   vWA: 17,18 (CLS; Cosmic-CLP; DSMZ; PubMed=25877200)
ST   vWA: 18 (PubMed=25056119)
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   PubMed=405430; DOI=10.1111/1523-1747.ep12496554;
RA   Foa C., Aubert C.;
RT   "Cellular localization of tyrosinase in human malignant melanoma cell
RT   lines.";
RL   J. Invest. Dermatol. 68:369-378(1977).
//
RX   PubMed=954556; DOI=10.1016/0014-2964(76)90033-5;
RA   Aubert C., Lagrange C., Rorsman H., Rosengren E.;
RT   "Catechols in primary and metastatic human malignant melanoma cells in
RT   monolayer culture.";
RL   Eur. J. Cancer 12:441-445(1976).
//
RX   PubMed=1822769; DOI=10.1097/00008390-199104000-00002;
RA   Karg E., Odh G., Rosengren E., Wittbjer A., Rorsman H.;
RT   "Melanin-related biochemistry of IGR 1 human melanoma cells.";
RL   Melanoma Res. 1:5-13(1991).
//
RX   PubMed=4153924;
RA   Janiaud P., Le Calvez J., Aubert C.;
RT   "Cytoenzymological caracterization of cells from human skin melanoma
RT   in culture.";
RL   Ann. Dermatol. Syphiligr. (Paris). 100:536-539(1973).
//
RX   PubMed=6929009; DOI=10.1093/jnci/64.5.1029;
RA   Aubert C., Rouge F., Galindo J.R.;
RT   "Tumorigenicity of human malignant melanocytes in nude mice in
RT   relation to their differentiation in vitro.";
RL   J. Natl. Cancer Inst. 64:1029-1040(1980).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25056119; DOI=10.1158/0008-5472.CAN-14-1232-T;
RA   Watson I.R., Li L.-R., Cabeceiras P.K., Mahdavi M., Gutschner T.,
RA   Genovese G., Wang G.-C., Fang Z.-N., Tepper J.M., Stemke-Hale K., Tsai K.Y.,
RA   Davies M.A., Mills G.B., Chin L.;
RT   "The RAC1 P29S hotspot mutation in melanoma confers resistance to
RT   pharmacological inhibition of RAF.";
RL   Cancer Res. 74:4845-4852(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//